OBJECTIVE: Glycoprotein (GP) Ibalpha is the functionally dominant subunit of the platelet GPIb-IX-V receptor complex. The N-terminal domain of the GPIbalpha chain contains binding sites for alpha-thrombin and von Willebrand factor (VWF). The human platelet alloantigen (HPA)-2 polymorphism of the GPIbalpha gene is associated with a C/T transition at nucleotide 1018, resulting in a Thr/Met dimorphism at residue 145 of GPIbalpha. To study the structural and functional effects of this dimorphism, N-terminal fragments (AA1-289) of the HPA-2a and HPA-2b alloform of GPIbalpha expressed in CHO cells were used. METHODS AND RESULTS: Of 74 moAbs directed against human GPIbalpha, 2 antibodies with epitope between AA1-59 could differentiate between both alloforms. In addition, VWF bound with a higher affinity to the recombinant HPA-2a fragment or to homozygous HPA-2a platelets. In contrast, no difference was found in the binding of alpha-thrombin to the recombinant alloform fragments or of antibodies directed against the alpha-thrombin binding anionic sulfated tyrosine sequence (AA269-282). CONCLUSIONS: Whereas the Thr145Met dimorphism does not affect alpha-thrombin binding, it does influence the conformation of the N-terminal flanking region and first leucine-rich repeat of GPIbalpha and by this has an effect on VWF binding.
OBJECTIVE:Glycoprotein (GP) Ibalpha is the functionally dominant subunit of the platelet GPIb-IX-V receptor complex. The N-terminal domain of the GPIbalpha chain contains binding sites for alpha-thrombin and von Willebrand factor (VWF). The humanplatelet alloantigen (HPA)-2 polymorphism of the GPIbalpha gene is associated with a C/T transition at nucleotide 1018, resulting in a Thr/Met dimorphism at residue 145 of GPIbalpha. To study the structural and functional effects of this dimorphism, N-terminal fragments (AA1-289) of the HPA-2a and HPA-2b alloform of GPIbalpha expressed in CHO cells were used. METHODS AND RESULTS: Of 74 moAbs directed against humanGPIbalpha, 2 antibodies with epitope between AA1-59 could differentiate between both alloforms. In addition, VWF bound with a higher affinity to the recombinant HPA-2a fragment or to homozygous HPA-2a platelets. In contrast, no difference was found in the binding of alpha-thrombin to the recombinant alloform fragments or of antibodies directed against the alpha-thrombin binding anionic sulfated tyrosine sequence (AA269-282). CONCLUSIONS: Whereas the Thr145Met dimorphism does not affect alpha-thrombin binding, it does influence the conformation of the N-terminal flanking region and first leucine-rich repeat of GPIbalpha and by this has an effect on VWF binding.
Authors: Judith M E M Cosemans; Saskia E M Schols; Lucia Stefanini; Susanne de Witt; Marion A H Feijge; Karly Hamulyák; Hans Deckmyn; Wolfgang Bergmeier; Johan W M Heemskerk Journal: Blood Date: 2010-10-29 Impact factor: 22.113
Authors: Marlene S Williams; Ethan J Weiss; Marc S Sabatine; Daniel I Simon; Wadie F Bahou; Lewis C Becker; Leslie V Parise; Harold L Dauerman; Patricia A French; Susan S Smyth; Richard C Becker Journal: Arterioscler Thromb Vasc Biol Date: 2010-12 Impact factor: 8.311
Authors: Minna Pellikka; Lassi Narhi; Markus Perola; Antti Penttila; Pekka J Karhunen; Jussi Mikkelsson Journal: J Thromb Thrombolysis Date: 2007-07-11 Impact factor: 2.300
Authors: Simon F De Meyer; Karen Vanhoorelbeke; Marinee K Chuah; Inge Pareyn; Veerle Gillijns; Robert P Hebbel; Désiré Collen; Hans Deckmyn; Thierry VandenDriessche Journal: Blood Date: 2006-02-14 Impact factor: 22.113
Authors: Julia Cavalcante do Carmo; Prissyla de Souza Klippel; Sabrine da Costa Cordeiro; Ângela Maria Dos Santos Fernandes; Raquel Medeiros Pinto; Simone Schneider Weber; Cleiton Fantin Journal: Rev Bras Hematol Hemoter Date: 2017-02-22